Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Supergen (supg) -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (45)	1/19/1999 12:20:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 124

RB, My guess is that SPTA had about 6 months cash, and no prospect of new financing given they were recently exiled to BB land and already had a bunch of Preferred outstanding. Haven't looked at their pipeline closely, but one has to assume there's nothing too dramatic there given the price of today's deal. However, if you collect a bunch of compatible niche products together, you can still make a very nice business. Peter

To: Russian Bear who wrote (45)	2/2/1999 8:27:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 124

Hi Russian Bear, I followed Sparta closely. Excellent model to advance products. Poorly managed from a shareholder's perspective. I didn't buy SPTA until after the reverse. I targeted it as a buy at .40 only based on technicals. Clearly the product pipeline is much much more valuable than that. SPTA shareholders clearly got snookered. The most attractive product is the diabetic product. I'm not sure if that will transfer to SUPG also. I know SPTA was looking at creating subsidiary to fund and develop the product. SUPG essentially got a gold mine of products. BEST WISHES LONE WOLF